Clinical trial NCT06092658: Cohort Study of Chronic Heart Failure
Official title: Cohort Study of Chronic Heart Failure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Analyze Etiology, Comorbidities, Clinical Characteristics
Lead sponsor: Xinjiang Medical University
Sponsor class: OTHER
First posted: 2023-10-23
Enrollment: 20000
Sex: ALL
Minimum age (years): 19
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE

Brief summary: The purpose is to understand the clinical characteristics of chronic heart failure as soon as possible, analyze the etiology, comorbidities, clinical characteristics, and treatment of heart failure patients, observe the gap between real-world clinical practice and guideline recommendations, and provide reference for the improvement of heart failure prevention and treatment in China.

Detailed description: Inclusion criteria:

1. Accompanied by difficulty breathing, fatigue, or decreased activity tolerance;
2. Signs of fluid retention (pulmonary congestion and peripheral edema);
3. Echocardiography shows abnormalities in cardiac structure and/or function;
4. Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L.
5. HF hospitalization recorded within the previous 12 months

Exclusion criteria:

1. Concomitant severe liver function, renal failure, or other severe system dysfunction
2. Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.

Eligibility criteria: Inclusion Criteria:

1. Accompanied by difficulty breathing, fatigue, or decreased activity tolerance;
2. Signs of fluid retention (pulmonary congestion and peripheral edema);
3. Echocardiography shows abnormalities in cardiac structure and/or function;
4. Elevated levels of natriuretic peptide: B-type natriuretic peptide (BNP)\>35 ng/L and/or N-terminal B-type proBNP (NT proBNP)\>125 ng/L.

Exclusion Criteria:

1. Concomitant severe liver function, renal failure, or other severe system dysfunction
2. Poor compliance, inability to obtain information, or voluntary refusal to participate in this study.

Primary outcomes:
measure: echocardiogram
timeFrame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
measure: cardiac marker
timeFrame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
measure: serum biochemical indicators
timeFrame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
Secondary outcomes:
measure: Thyroid Function
timeFrame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
measure: Coagulation function indicators
timeFrame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
measure: Blood routine
timeFrame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
measure: Blood routine
timeFrame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
measure: Blood routine
timeFrame: Follow up will be conducted at baseline, 6 months, 12 months, and 36 months
Other outcomes:
Locations:
Study officials:
References: